Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Prabhu Ram

Internal Medicine Attleboro, MA Medical Doctor

NPI 1013228980 CMS profile 847505

19 Sturdy St, Attleboro, MA 02703

Open in the dashboard

General payments

$10,520

568 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Prabhu Ram of Attleboro, MA is reported in the CMS Open Payments database as having received $10,520 across 568 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,703 123
2024 General $2,132 106
2023 General $1,355 68
2022 General $1,240 68
2021 General $1,541 91
2020 General $923 57
2019 General $626 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Prabhu Ram
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Prabhu Ram were reported at $2,703. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Prabhu Ram Internal Medicine median Middle half National median
2019 $626 $159 $48–$570 $163
2020 $923 $119 $33–$402 $114
2021 $1,541 $135 $37–$521 $132
2022 $1,240 $141 $42–$496 $149
2023 $1,355 $149 $45–$519 $160
2024 $2,132 $154 $47–$537 $164
2025 $2,703 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $1,609 88 payments
  2. Pfizer Inc. $1,275 91 payments
  3. AbbVie, Inc. $1,116 62 payments
  4. AstraZeneca Pharmaceuticals LP $938 45 payments
  5. Novo Nordisk Inc $865 46 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $690 37 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $538 19 payments
  8. GlaxoSmithKline, LLC. $506 27 payments
  9. Merck Sharp & Dohme Corporation $447 26 payments
  10. Novartis Pharmaceuticals Corporation $370 21 payments
  11. Other $2,167 106 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,512 566 payments
  2. Education $8 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $885 50 payments
  2. JARDIANCE $686 37 payments
  3. Ozempic $587 32 payments
  4. Kerendia $538 19 payments
  5. COLOGUARD $523 48 payments
  6. RYBELSUS $439 24 payments
  7. MOUNJARO $417 23 payments
  8. FARXIGA $396 17 payments
  9. EUCRISA $364 34 payments
  10. STEGLATRO $335 19 payments
  11. Other $8,854 495 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

2,728

Median for Internal Medicine: 777

Drug cost

$347,214

Median for Internal Medicine: $73,373

Branded share of claims

23.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 11 $49,929
Mounjaro Tirzepatide Brand 35 $38,373
Jardiance Empagliflozin Brand 28 $37,831
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 49 $35,881
Trulicity Dulaglutide Brand 26 $34,306
Januvia Sitagliptin Phosphate Brand 28 $26,239
Farxiga Dapagliflozin Propanediol Brand 18 $23,409
Eliquis Apixaban Brand 28 $20,058
Xarelto Rivaroxaban Brand 15 $19,303
Tradjenta Linagliptin Brand 18 $18,868

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$44,881

Medicare's payments for the services billed

Medicare patients

93

Average age 71

Services billed

475

39 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 34%
Arthritis 34%
Ischemic heart disease 23%
Depression 19%
COPD 18%
Chronic kidney disease 14%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $119
  • Boehringer Ingelheim Pharmaceuticals, Inc. $36
$155 28 —
UBRELVY
  • AbbVie, Inc. $143
$143 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $141
$141 — —
JATENZO
  • TOLMAR, INC. $123
$123 — —
MOUNJARO
  • Lilly USA, LLC $111
$111 35 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

568 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record